TY - JOUR T1 - Effect of indacaterol/mometasone on lung function in adolescents versus overall patient population: PALLADIUM study JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2020.2283 VL - 56 IS - suppl 64 SP - 2283 AU - Matthias Krüll AU - Richard Van Zyl-Smit AU - Christian Gessner AU - Yasuhiro Gon AU - Oliver Noga AU - Alexia Richard AU - Amy De Los Reyes AU - Xu Shu AU - Abhijit Pethe AU - Ana-Maria Tanase AU - Peter D'Andrea Y1 - 2020/09/07 UR - http://erj.ersjournals.com/content/56/suppl_64/2283.abstract N2 - Aim: This analysis from the PALLADIUM study (NCT02554786) evaluated the effect of IND/MF medium- and high-dose on lung function in adolescent (12–17 yrs) patients (pts) and overall population with inadequately controlled asthma.Methods: This 52 wk, double-blind, parallel-group study included 2216 pts (≥12–≤75 yrs), of which 107 were adolescents, having a pre-bronchodilator FEV1 ≥50%–<85% and ACQ-7 ≥1.5 at screening. The effect of IND/MF medium- (150/160µg) and high-dose (150/320µg) o.d. via Breezhaler® vs respective MF doses (400µg o.d. and 400µg b.i.d.) via Twisthaler® and IND/MF high-dose via Breezhaler® vs Sal/Flu high-dose (50/500µg b.i.d) via Diskus® on trough FEV1, PEF and post-dose FEV1 was assessed.Results: In adolescents, IND/MF improved trough FEV1 (at Wk 26) and PEF (over 52-wks) to a greater extent vs MF, with a rapid onset of action (post-dose FEV1); the data was in line with the overall population (Table). IND/MF high-dose showed comparable results in trough FEV1 and PEF vs Sal/Flu high-dose in adolescents, whereas in the overall population, greater improvements in PEF were observed with IND/MF.Conclusion: A greater improvement in lung function and a rapid onset of action with IND/MF high- and medium-dose o.d. vs respective MF doses was observed in adolescents, and are consistent with the overall patient population. FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 2283.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -